Personalis (PSNL) announced new data from an AstraZeneca (AZN) Phase 3 clinical trial in lung cancer, LAURA, demonstrating that Personalis’ NeXT Personal molecular residual disease test is a useful tool in assessing the maintenance treatment response post-chemoradiotherapy in patients with unresectable stage III, EGFR-mutated non-small cell lung cancer. The analysis, to be presented at the ESMO 2025 Conference, showed NeXT Personal detected molecular residual disease progression with a median lead time of five months ahead of standard review.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis management to meet with Piper Sandler
- Personalis collaborates with Yale Cancer Center over CATE clinical trial
- Buy Rating for Personalis Driven by Promising Clinical Data and Strategic Reimbursement Efforts
- Personalis reports data from AstraZeneca phase 3 clinical trial in lung cancer
- Personalis Secures New VA Contract Task Order